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Abstract
Background: Accumulative evidence suggests that low folate intake is associated with increased risk of breast
cancer. Polymorphisms in genes involved in folate metabolism may influence DNA methylation, nucleotide
synthesis, and thus individual susceptibility to cancer. Thymidylate synthase (TYMS) is a key enzyme that
participates in folate metabolism and catalyzes the conversion of dUMP to dTMP in the process of DNA synthesis.
Two potentially functional polymorphisms [a 28-bp tandem repeat in the TYMS 5'-untranslated enhanced region
(TSER) and a 6-bp deletion/insertion in the TYMS 3'-untranslated region (TS 3'-UTR)] were suggested to be
correlated with alteration of thymidylate synthase expression and associated with cancer risk.
Methods: To test the hypothesis that polymorphisms of the TYMS gene are associated with risk of breast cancer,
we genotyped these two polymorphisms in a case-control study of 432 incident cases with invasive breast cancer
and 473 cancer-free controls in a Chinese population.
Results: We found that the distribution of TS3'-UTR (1494del6) genotype frequencies were significantly different
between the cases and controls (P = 0.026). Compared with the TS3'-UTR del6/del6 wild-type genotype, a
significantly reduced risk was associated with the ins6/ins6 homozygous variant genotype (adjusted OR = 0.58,
95% CI = 0.35–0.97) but not the del6/ins6 genotype (OR = 1.09, 95% CI = 0.82–1.46). Furthermore, breast cancer
risks associated with the TS3'-UTR del6/del6 genotype were more evident in older women, postmenopausal
subjects, individuals with a younger age at first-live birth and individuals with an older age at menarche. However,
there was no evidence for an association between the TSER polymorphism and breast cancer risks.
Conclusion: These findings suggest that the TS3'-UTR del6 polymorphism may play a role in the etiology of breast
cancer. Further larger population-based studies as well as functional evaluation of the variants are warranted to
confirm our findings.
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Background
Breast cancer is the leading cause of cancer-related deaths
for women in China, and the incidence rate is still increas-
ing [1]. A wide diversity of genetic damage induced by
endogenous metabolites and exogenous hazards may
contribute to the etiology of breast cancer. Epidemiologi-
cal studies suggested that folate-deficient diet may
increase the risk for breast cancer [2-5]. Folate, often in the
form of folic acid, is essential for DNA methylation, DNA
synthesis, and DNA repair [6,7]. Chronic folate/methyl
deficiency in vivo and in vitro has been associated with
DNA strand breaks [8-10] and abnormal DNA methyla-
tion [11,12] that may lead to carcinogenesis.
Many enzymes are involved in folate metabolism, among
which, thymidylate synthase (TYMS) catalyzes the conver-
sion of deoxyuridine monophosphate (dUMP) to deox-
ythymidine monophosphate (dTMP), using the 5, 10-
methylenetetrahydrofolate as a methyl donor [13]. This
conversion is essential for the provision of thymidine, a
nucleotide needed for DNA synthesis and DNA repair
[14]. In thymidylate synthase-negative mutants of mouse
FM3A cells, thymidine starvation results in thymineless
death via the induction of DNA double-strand breaks that
lead to chromosome fragmentation as well as rearrange-
ments in the cells synthesizing DNA [15]. Therefore,
genetic alterations in TYMS enzyme efficiency and/or
expression level may contribute to individual susceptibil-
ity to breast cancer.
The TYMS gene is located in chromosome 18p11.32. A
tandem repeat polymorphism has been identified in the
5'-UTR enhancer region of the TYMS promoter (TSER),
the immediate upstream of the ATG codon initiation start
site, which contains triple (TSER 3R) or double (TSER 2R)
repeats of a 28-bp sequence as well as several rare alleles
containing 4, 5 or 9 repeats [16]. In vitro and in vivo studies
showed that TYMS expression was TSER  genotype-
dependent and that the 3R allele was associated with a
higher TYMS expression level [16,17]. Recently, a novel
polymorphism, a 6-bp deletion/insertion in the 3'-
untranslated region of the TYMS gene (TS3'-UTR del6),
has also been identified, which may have an effect on the
TYMS mRNA stability and translation [18], perhaps affect-
ing TYMS protein expression level as well. Therefore, the
above two TYMS variants are thought to be functionally
relevant and are hypothesized to be associated with risk of
breast cancer. To test this hypothesis, we performed geno-
typing analyses for TS 5'-UTR TSER and TS 3'-UTR del6
polymorphisms in a case-control study of 432 incident
cases with invasive breast cancer and 473 cancer-free con-
trols in a Chinese population.
Methods
Study population
This hospital-based case-control study consisted of 432
patients who received surgical treatment for solitary mam-
mary lumps, which were histopathologically diagnosed as
invasive breast cancer, and 473 cancer-free controls. All
subjects were genetically-unrelated ethnic Han Chinese
and were from Nanjing city and surrounding regions in
Jiangsu Province. The breast cancer patients were consec-
utively recruited between January 2004 and July 2005 at
the Cancer Hospital of Jiangsu Province, the First Affili-
ated Hospital of Nanjing Medical University and the Nan-
jing Gulou Hospital, Nanjing, China. Those patients who
had any previous cancers, in situ breast cancer (DCIS),
metastasized cancer originated from other organs, and
previous radiotherapy or chemotherapy were excluded.
Cancer-free controls were randomly selected from a pool
of 10,500 individuals who participated in a community-
based screening program for non-infectious diseases con-
ducted in Jiangsu Province during the same time period as
the cases were recruited. These control subjects had no
self-reported cancer history and were frequency-matched
to the cases on age (± 5 years) and residential areas. Each
subject was scheduled for an interview after an informed
consent was obtained, and a structured questionnaire was
administered by interviewers to collect information on
demographic data, menstrual and reproductive history,
family history of cancer (any kind of cancers in first-
degree relatives) and environmental exposure history.
After the interview, an approximately 5-ml venous blood
sample was collected from each subject. The study was
approved by the institutional review board of Nanjing
Medical University.
Genotype analyses
By centrifugation of 5-ml whole blood, genomic DNA was
extracted from the leukocyte pellet obtained from the
buffy coat of each blood sample. We used the previously-
described genotyping assays for the two loci of TYMS [19].
Briefly, we used pairs of primers of 5'-GTGGCTCCT-
GCGTTTCCCCC-3' (forward) and 5'-GGCTCCGAGCCG-
GCCACAGGCATGGCGCGG-3' (reverse) to genotype the
TSER locus and 5'-CAAATCTGAGGGAGCTGAGT-3' (for-
ward) and 5'-CAGATAAGTGGCAGTACAGA-3' (reverse)
to genotype the TS 3'-UTR del6 locus. For the TSER poly-
morphism, 243 bp (i.e. 3R), 215 bp (i.e. 2R), 271 bp (i.e.
4R) and 299 bp (i.e. 5R) fragments were identified and
separated on 3% agarose gels. For the TS 3'-UTR del6 pol-
ymorphism, 152 bp (i.e. del6) or 158 bp fragments (i.e.
ins6) were amplified and then digested by Dra I (New
England BioLabs, Inc., Beverly, MA). The variant (ins6)
allele produces two fragments of 88 and 70 bp, while the
wild-type (del6) allele produces a single 152-bp fragment.
Genotyping was performed without knowing the subjects'
case or control status, and approximately equal number ofBMC Cancer 2006, 6:138 http://www.biomedcentral.com/1471-2407/6/138
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cases and controls were assayed in each 96-well PCR plate
with a positive control of a DNA sample with a known
heterozygous genotype. If a consensus on the tested geno-
type was not reached, two research assistants independ-
ently performed the repeated assays to achieve 100%
concordance. More than 10% of the samples were
repeated using the same assay and the results were 100%
concordant.
Statistical analyses
Differences in demographic characteristics, selected varia-
bles, and frequencies of the genotypes, alleles, and haplo-
types of TSER and TS 3'-UTR del6 between the cases and
controls were evaluated using the χ2 test (for categorical
variables) and student t-test (for continuous variables).
The associations between TSER and TS 3'-UTR del6 variant
genotypes and breast cancer risk were estimated by com-
puting ORs and their 95% CIs from both univariate and
multivariate logistic regression analyses. Linkage disequi-
librium (LD) between the two loci of TYMS was estimated
using the EH algorithm available online [20]. We used the
PHASE 2.0 program [21] to infer the haplotype frequen-
cies, based on the observed TYMS  genotypes. Hardy-
Weinberg equilibrium was tested by a goodness-of-fit χ2
test to compare the observed genotype frequencies with
the expected frequencies among the control subjects. All
the statistical analyses were performed with Statistical
Analysis System software (v.9.03e; SAS Institute, Cary,
NC).
Results
The selected characteristics and distributions of TSER and
TS 3'-UTR del6 alleles/haplotypes of the 432 breast cancer
cases and 473 cancer-free controls are summarized in
Table 1. The frequency-matching on age between cases
and controls was adequate as suggested by a non-signifi-
cant p value with the student t test. Compared with con-
trol subjects, breast cancer patients had a lower age at
menarche (P <0.0001) and a higher age at having first live
birth (P <0.0001). Among the 498 postmenopausal sub-
jects, the menopausal age of breast cancer cases was lower
than that of the controls (P  = 0.02). There were 113
(26.2%) breast cancer cases and 95 (20.1%) controls
reported a family history of cancer, which was associated
with a significantly increased risk for breast cancer (OR =
1.41, 95% CI = 1.03–1.92).
The allele frequencies of TSER 2R and TS 3'-UTR ins6 were
0.204 and 0.331, respectively, in the controls, while they
were 0.202 and 0.310, respectively, in the cases, and the
differences were not statistically significant (P = 0.987 for
TSER and P = 0.347 for TS 3'-UTR del6) (Table 1). In the
linkage disequilibrium (LD) analyses, we found that the
TSER locus was partially in LD with the TS 3'-UTR del6
Table 1: Comparison of breast cancer cases and controls by selective characteristics
Variable Controlsc (n = 473) Breast cancer (n = 432) P value
Age, yr (mean ± SD) 51.42 ± 11.12 52.09 ± 11.03 0.36
Age at menarche, yr (mean ± SD) 16.40 ± 1.77 15.32 ± 1.92 <0.0001
Age at first live birth, yr (mean ± SD) a 24.49 ± 2.47 25.51 ± 3.45 <0.0001
Age at menopausal, yr (mean ± SD) b 49.79 ± 3.88 48.89 ± 4.26 0.02








3R allele 753(79.6) 688(79.8)
2R allele 193(20.4) 176(20.2)
TS 3'-UTR del6 0.347
del6 allele 633(66.9) 596(69.0)
ins6 allele 313(33.1) 268(31.0)





a Age at first live birth information was available in 460 controls and 419 breast cancer cases.
b Age at menopausal information was available in 226 controls and 227 breast cancer cases with postmenopausal status.
cThree controls carrying the rare alleles of more than three 28 bp repeats (>3R) were excluded in the current analyses.BMC Cancer 2006, 6:138 http://www.biomedcentral.com/1471-2407/6/138
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locus (D' = 0.584; R2 = 0.186, P <0.001). There were four
haplotypes derived from the observed TYMS genotypes,
but there was no significant difference in the distribution
of haplotypes between the cases and controls (P = 0.863)
(Table 1).
The TSER and TS 3'-UTR del6 genotype distributions in
the cases and controls were shown in Table 2. The geno-
type frequencies for these two polymorphisms were both
in agreement with Hardy-Weinberg equilibrium in the
controls (χ2 = 2.26, df = 1, P = 0.13 for TSER and χ2 = 0.77,
df = 1, P = 0.38 for TS 3'-UTR del6). The TSER genotype
frequencies were 64.5% (3R/3R), 30.2% (2R/3R) and
5.3% (2R/2R), respectively, among controls, which were
not significantly different from those of the cases (64.6%
3R/3R, 30.1% 2R/3R and 5.3% 2R/2R) (P = 0.999). Mul-
tivariate logistic regression analyses revealed that both 2R/
3R and 2R/2R genotypes were not significantly associated
with breast cancer risk (adjusted OR = 0.95, 95% CI =
0.70–1.29 for 2R/3R and OR = 1.13, 95% CI = 0.61–2.10
for 2R/2R, respectively), compared with the TYMS 3R/3R
genotype, (Table 2). Likewise, the frequencies of TS 3'-
UTR del6 genotype were 45.7% (del6/del6), 42.5% (del6/
ins6), and 11.8% (ins6/ins6), respectively, in control sub-
jects and 44.9% (del6/del6), 48.1% (del6/ins6), and 6.9%
(ins6/ins6), respectively, in breast cancer patients, and the
overall difference was statistically significant (P = 0.026).
Compared with TS 3'-UTR del6/del6 wild-type genotype, a
significantly reduced risk was associated with ins6/ins6
homozygous variant genotype (adjusted OR = 0.58, 95%
CI = 0.35–0.97), but it was not related with del6/ins6 het-
erozygous genotype (OR = 1.09, 95% CI = 0.82–1.46).
(Table 2)
Because age, menopausal status, age at menarche, age at
first live birth and family history of cancer were the well
accepted risk factors for breast cancer, we performed strat-
ification analyses by these variables to assess risk modifi-
cation by the TYMS genotypes. We found that reduced
breast cancer risk associated with TS 3'-UTR del6 variant
genotype was more evident in older women (adjusted OR
= 0.53, 95% CI = 0.28–1.00), postmenopausal women
(adjusted OR = 0.45; 95% CI = 0.22–0.90), individuals
with a younger first live birth age (adjusted OR = 0.47;
95% CI = 0.22–1.03) and individuals with a later
menarche age (adjusted OR = 0.39; 95% CI = 0.19–0.81)
(Table 3). However, we did not find any statistical evi-
dence for any interaction on a multiplicative scale
between the variant genotypes and potential risk factors of
breast cancer (data not shown).
Discussion
In this hospital-based case-control study, we investigated
the associations of one promoter SNP TSER and a TS 3'-
UTR del6 polymorphism in the 3'-UTR of the TYMS gene
with risk of breast cancer in a Chinese population. We
found, for the first time, that the TS 3'-UTR ins6/ins6 gen-
otype was associated with a significantly decreased risk of
breast cancer, and the associations were more evident in
older women, postmenopausal women, individuals with
a younger first live birth age and individuals with a later
menarche age. These findings suggest that the TS 3'-UTR
variant may contribute to the etiology of breast cancer in
our Chinese population.
Although the promoter TSER polymorphism was identi-
fied in a cis-acting enhancer element of the TYMS gene
and is thought to affect TYMS  mRNA expression
[16,17,22], several molecular epidemiological studies
reported contrary results of the associations between this
variant and cancer risk [19,23-34]. In the only one study
on breast cancer, the TSER variant was found not to con-
tribute to the risk of breast cancer in an Australian popu-
lation, which is consistent with our current study in
Chinese women [27].
The TS 3'-UTR del6 polymorphism is located in the 3'UTR
of TYMS gene, and the function of this variant has not yet
Table 2: TSER and TS 3'-UTR del6 genotype frequencies among breast cancer cases and controls
Genotype Controls (N = 473) Breast cancer (N = 432)
N (%) N (%) aAdjusted OR (95% CI)
TSER
3R/3R (reference) 305(64.5) 279(64.6) 1.00
2R/3R 143(30.2) 130(30.1) 0.95(0.70–1.29)
2R/2R 25(5.3) 23(5.3) 1.13(0.61–2.10)
2R/3R and 2R/2R 168(35.5) 153(35.4) 0.98(0.73–1.30)
TS3'-UTR del6
del6/del6 (reference) 216(45.7) 194(44.9) 1.00
del6/ins6 201(42.5) 208(48.1) 1.09(0.82–1.46)
ins6/ins6 56(11.8) 30(6.9) 0.58(0.35–0.97)
a Adjusted for age, age at menarche, menopausal status, BMI and family history of cancerBMC Cancer 2006, 6:138 http://www.biomedcentral.com/1471-2407/6/138
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been fully understood. Available limited phenotype stud-
ies reported that the wild-type del6 allele may be associ-
ated with decreased stability of TYMS in vitro, lower
intratumoral TYMS expression in vivo and perhaps with
increased risk for cancers [35], which is consistent with
our present association study that the variant ins6 allele is
associated with a decreased breast cancer risk. Because
TYMS plays an important role in folate metabolism,
which is essential for DNA methylation, synthesis, and
repair, our findings provide some evidence for the under-
line molecular mechanism of the association between
folate metabolism and breast cancer susceptibility.
Recently, a few studies have investigated the association
between the TS 3'-UTR del6 polymorphism and risk of
several types of cancer, but the results were mixed
[19,23,26,28-30,34]. Graziano et al found that the TS 3'-
UTR ins6 allele was protective against gastric cancer in
Caucasians [28]. However, three recent studies reported
that the TS 3'-UTR ins6/ins6 and/or del6/ins6 +ins6/ins6
genotypes were associated with a significantly increased
risk for gastric cancer, SCCNH and lung cancer [19,23,26],
while some other studies did not observe any associations
between this polymorphism and cancer risk [29,30,34]. In
the present study, we found, for the first time, that the TS
3'-UTR ins6/ins6 homozygous variant genotype was asso-
ciated with a significantly decreased risk of breast cancer
in a Chinese population, and this significantly protective
effect was more evident in postmenopausal women, indi-
viduals with a younger first live birth age or individuals
with later menarche age. These findings suggest that TYMS
polymorphisms may be potential genetic markers of
breast cancer risk modified by reproductive hormone lev-
els of the subjects in their lifetime as indicated in
menarche age, first live birth age, and menopausal status.
However, because of the small sample size in the sub-
groups, these findings were considered preliminary and
need to be validated in further studies with larger sample
sizes in these subpopulations. The discrepancies between
available association studies in relation to this variant
may be due to different etiologies and mechanisms of dif-
ferent cancers, different ethnic backgrounds of popula-
tions, uncharacterized environmental exposure factors,
and/or potential biases because of the small sample size
of related studies.
Genetic polymorphisms often vary between ethnic
groups. In the present study in a Chinese population, the
frequencies of TSER 3R/3R, 2R/3R and 2R/2R genotypes
were 64.5%, 30.2% and 5.3%, respectively, among 473
control subjects, which were not different from those
among the 322 controls in a gastric cancer study in Chi-
nese (63.0% 3R/3R, 33.3% 2R/3R and 3.7% 2R/2R, P =
0.447) that we previously reported [19]. However, Marsh
et al [36] showed a significantly ethnic variation of TSER
variant that homozygous triple repeat was twice as com-
mon in Chinese subjects (67%) as in Caucasians (38%).
Similarly, we found that the allele frequency of TS 3'-UTR








del6/del6 del6/ins6 ins6/ins6 del6/del6 del6/ins6 ins6/ins6
Age
≤ 48 158/195 80/98 69/76 9/21 1.00 1.11(0.70–1.76) 0.65(0.27–1.56)
> 48 274/278 114/118 139/125 21/35 1.00 1.08(0.74–1.58) 0.53(0.28–1.00)
Menopausal status
Premenopausal 197/210 93/105 90/82 14/23 1.00 1.22(0.80–1.86) 0.75(0.36–1.56)
Postmenopausal 235/263 101/111 118/119 16/33 1.00 1.01(0.68–1.50) 0.45(0.22–0.90)
Age at menarche
<16 239/152 103/70 117/69 19/13 1.00 1.06(0.68–1.64) 0.87(0.39–1.91)
≥16 193/321 91/146 91/132 11/43 1.00 1.13(0.77–1.65) 0.39(0.19–0.81)
bAge at first live birth
≤ 25 166/226 70/91 85/104 11/31 1.00 1.04(0.67–1.61) 0.47(0.22–1.03)
>25 253/234 116/118 120/95 17/21 1.00 1.24(0.82–1.87) 0.95(0.45–2.03)
Family history of cancer
No 319/378 143/173 155/165 21/40 1.00 1.07(0.77–1.48) 0.63(0.35–1.13)
Yes 113/95 51/43 53/36 9/16 1.00 1.27(0.69–2.35) 0.45(0.17–1.21)
aAdjusted for the other covariates presented in this table in a logistic regression model for each stratum.
b Age at first live birth information was available in 460 controls and 419 breast cancer cases.BMC Cancer 2006, 6:138 http://www.biomedcentral.com/1471-2407/6/138
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ins6 was 0.331 among the 473 control subjects, which is
also consistent with what was reported in Chinese popu-
lations (0.320, n = 348 from north China [29], and 0.309,
n = 322 from southeast China [19]), but it is much lower
than that of Caucasians (65% to 70%)[26,30,34].
The primary shortcoming of this study is the lack of data
on detailed dietary intake of folate, plasma or erythrocyte
folate levels and its precursors or metabolites such as
homocysteine, which limited our inquiry into potential
gene–nutrient interactions in breast carcinogenesis. Fur-
thermore, like all other hospital-based case-control stud-
ies, inherited biases may lead to spurious findings or false
positive results. Because our cases were from hospitals and
the controls were from the community, the study subjects
may not be fully representative of the general population.
However, we applied rigorous epidemiological designs by
limiting factors of selecting subjects and performed fur-
ther statistical adjustment to minimize these potential
biases. The agreement with Hardy-Weinberg equilibrium
of these two loci of TYMS gene and similar allele frequen-
cies of our controls to those reported from other Asian
populations suggests that the selection bias would not be
substantial in terms of genotype distribution. Finally,
although we have 94% statistical power to achieve the
main effect of the study, we have very limited power in the
stratified analyses because of the small sample size of the
subgroups. Therefore, large well-designed studies are war-
ranted to further confirm our findings.
Conclusion
Our study provides some new evidence that the TS 3'-UTR
ins6/ins6 genotype may contribute to the etiology of breast
cancer. Studies in diverse ethnic populations and simulta-
neous measurements of detailed data of the TYMS geno-
types as well as its phenotypes, accompanied by multiple
SNPs of other important one-carbon metabolism genes
and information of folate intake are warranted to further
elucidate gene-gene and gene-environment interactions in
susceptibility of breast cancer.
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